A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
Price : $35 *
At a glance
- Drugs CDX 301 (Primary) ; Plerixafor (Primary)
- Indications Stem cell mobilisation
- Focus Adverse reactions
- Sponsors Celldex Therapeutics Inc
- 31 Aug 2018 Biomarkers information updated
- 23 May 2016 Status changed from active, no longer recruiting to discontinued.
- 30 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.